Viatris Inc (VTRS)

Viatris Inc. is a healthcare company whose common stock is listed on NASDAQ under the ticker VTRS. Through its subsidiaries, the company operates across North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, the rest of Asia, Africa, Latin America, and the Middle East. Viatris is organized into four reporting segments: Developed Markets, Greater China, JANZ, and Emerging Markets.

The company develops and markets prescription brand medicines, generics, complex generics, and biosimilars across a range of therapeutic areas, including cardiovascular, central nervous system and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy. It also provides patient support services such as diagnostic clinics, educational seminars, and digital tools. Viatris sells its products to wholesalers, retailers, institutional pharmacies, mail-order and e-commerce pharmacies, specialty pharmacies, payers, insurers, governments, and institutions. Its portfolio includes brands such as Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, and Breyna. Founded in 1961, Viatris is headquartered in Canonsburg, Pennsylvania.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.